APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jiangsu Fangzhou Chemical / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/fangzhou-group" target="_blank" data-smartkarma-citation="entities:36560:1" rel="noopener">Fangzhou Group (FANGZHOU HK)</a> is looking to raise about US$300m in its upcoming Hong Kong IPO.</li>
<li>Fangzhou (FZ) is an online chronic disease management (CDM) service provider in China.</li>
<li>In this note, we will talk about the positive aspects of the deal.</li>
</ul>



Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming Hong Kong IPO.
Fangzhou (FZ) is an online chronic disease management (CDM) service provider in China.
In this note, we will talk about the positive aspects of the deal.


Fangzhou Pre-IPO - The Positives - Regulatory Changes and COVID Spurred Growth

Ethan Aw

<ul>
<li>
<a href="https://www.smartkarma.com/entities/fangzhou-group" target="_blank" data-smartkarma-citation="entities:36560:1" rel="noopener">Fangzhou Group (FANGZHOU HK)</a> is looking to raise about US$300m in its upcoming HK IPO. The deal will be run by Citibank, UBS and ABC International. </li>
<li>Fangzhou Group is an online chronic disease management platform in China, considered the largest in terms of average MAU in 2021, according to CIC.</li>
<li>It focuses on common and chronic diseases such as hypertension, cardiovascular and respiratory chronic diseases, providing tailored medical care and precision medicine covering the full disease cycle for patients.</li>
</ul>



Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming HK IPO. The deal will be run by Citibank, UBS and ABC International. 
Fangzhou Group is an online chronic disease management platform in China, considered the largest in terms of average MAU in 2021, according to CIC.
It focuses on common and chronic diseases such as hypertension, cardiovascular and respiratory chronic diseases, providing tailored medical care and precision medicine covering the full disease cycle for patients.


China

Jiangsu Fangzhou Chemical Co., Ltd. was founded in 1998. The company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparations for human or veterinary use.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jiangsu Fangzhou Chemical (AATZCZ CH)

Fangzhou Pre-IPO - The Positives - Regulatory Changes and COVID Spurred Growth

Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming Hong Kong IPO. In this note, we will talk about the positive aspects...

Clarence Chu

Fangzhou Group Pre-IPO Tearsheet

Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming HK IPO. The deal will be run by Citibank, UBS and ABC International.

Ethan Aw

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)